Trial Profile
A study evaluating safety and efficacy of Venetoclax in chronic lymphocytic leukemia patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Dec 2017
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 20 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology